Six years ago, Canadian pharmaceutical firm Theratechnologies opened the doors of its European beachhead in Dublin. The company’s Irish boss told Fora in 2019 that the Montreal-headquartered firm had set up shop in Dublin to expand into the European market and would grow the staff to “numbers of note”. It develops HIV therapies, namely its Trogarzo drug, which was registered with the European Medicines Agency through the Dublin address. But over the last few years, the company has been quietly winding up the Irish base and turning its focus away from Europe and back to the North American market. This…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €50.

Subscribe

Cancel at any time.

Are you already a member? .